Research and development of drugs for neglected conditions has been slow, with only 37 of the 850 vaccines and medicines approved in the past 10 years intended for such diseases, according to a study in The Lancet Global Health. This sluggish growth can be attributed in part to a lack of financial rewards to spur drug and biotech firms to allocate funds for the development of therapies for conditions such as malaria and Chagas disease, the study notes.

Full Story:
Voice of America

Related Summaries